Bladder-Sparing Treatment With Disitamab Vedotin and Toripalimab With or Without Pelvic Lymph Node Dissection in Bladder Cancer
A Prospective, Multicenter, Randomized Controlled Study of Disitamab Vedotin Plus Toripalimab With or Without Pelvic Lymph Node Dissection for Bladder-Sparing Treatment in Patients With cT2-3N0M0 Bladder Urothelial Carcinoma
研究概览
地位
详细说明
Muscle-invasive bladder cancer is commonly treated with radical cystectomy; however, bladder-sparing strategies are needed for selected patients who decline cystectomy. This study evaluates a bladder-sparing strategy based on maximal transurethral resection of bladder tumor, disitamab vedotin plus toripalimab, and the addition of standardized pelvic lymph node dissection.
Participants will be randomized to receive disitamab vedotin plus toripalimab with or without pelvic lymph node dissection after maximal transurethral resection of bladder tumor. Tumor response will be assessed by imaging, cystoscopy or transurethral resection/biopsy when clinically indicated, and urine cytology. Participants who meet bladder-sparing criteria will enter bladder-intact follow-up according to the protocol. Safety, survival, quality of life, treatment cost, and exploratory biomarkers will also be evaluated.
研究类型
注册 (估计的)
阶段
- 阶段2
- 第三阶段
联系人和位置
学习联系方式
- 姓名:Hailong Hu
- 电话号码:+86 13662096232
- 邮箱:huhailong@tmu.edu.cn
研究联系人备份
- 姓名:Peng Li
- 电话号码:+86 18935803489
- 邮箱:lipeng990220@tmu.edu.cn
学习地点
-
-
Tianjin Municipality
-
Tianjin、Tianjin Municipality、中国、300211
- The Second Hospital of Tianjin Medical University
-
接触:
- Peng Li
- 电话号码:+86 18935803489
- 邮箱:lipeng990220@tmu.edu.cn
-
接触:
- Hailong Hu, MD,PhD
- 电话号码:+86 13662096232
- 邮箱:huhailong@tmu.edu.cn
-
-
参与标准
资格标准
适合学习的年龄
- 成人
- 年长者
接受健康志愿者
描述
Inclusion Criteria:
- Male or female participants aged 18 years or older.
- Histologically confirmed bladder urothelial carcinoma.
- Clinical stage cT2-3N0M0 according to the AJCC 8th edition TNM staging system.
- HER2 expression of IHC 2+ or higher.
- Participants who decline radical cystectomy as assessed by the investigator.
- Adequate organ function as defined in the study protocol.
- Ability to understand and willingness to sign written informed consent.
Exclusion Criteria:
- Known allergy or hypersensitivity to disitamab vedotin, toripalimab, their excipients, or other monoclonal antibodies.
- Prior radiotherapy for bladder cancer.
- Prior anticancer treatment that may affect efficacy assessment, as defined in the study protocol.
- Pregnant or breastfeeding women.
- Any serious uncontrolled disease or medical condition that, in the investigator's judgment, would make participation inappropriate.
- Participation in another interventional clinical trial that may interfere with this study.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Disitamab Vedotin Plus Toripalimab With Pelvic Lymph Node Dissection
Participants will receive maximal transurethral resection of bladder tumor followed by disitamab vedotin plus toripalimab and standardized pelvic lymph node dissection.
|
Disitamab vedotin will be administered in combination with toripalimab according to the study protocol.
Toripalimab will be administered in combination with disitamab vedotin according to the study protocol.
Maximal transurethral resection of bladder tumor will be performed as part of the bladder-sparing treatment strategy.
Standardized pelvic lymph node dissection will be performed in participants assigned to the PLND arm.
|
|
有源比较器:Disitamab Vedotin Plus Toripalimab Without Pelvic Lymph Node Dissection
Participants will receive maximal transurethral resection of bladder tumor followed by disitamab vedotin plus toripalimab without planned pelvic lymph node dissection.
|
Disitamab vedotin will be administered in combination with toripalimab according to the study protocol.
Toripalimab will be administered in combination with disitamab vedotin according to the study protocol.
Maximal transurethral resection of bladder tumor will be performed as part of the bladder-sparing treatment strategy.
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
2-year Bladder-intact Event-free Survival Rate
大体时间:24 months after randomization
|
The proportion of participants who remain alive with an intact bladder and without muscle-invasive bladder cancer recurrence, regional lymph node recurrence, distant metastasis, radical cystectomy, or bladder cancer-related death at 24 months after randomization.
|
24 months after randomization
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Clinical Complete Response Rate
大体时间:After completion of induction treatment, up to 12 weeks
|
The proportion of participants who achieve clinical complete response, defined as no visible tumor on imaging, no evidence of malignancy on cystoscopy or TURBT/biopsy when clinically indicated, and negative urine cytology.
For participants undergoing pelvic lymph node dissection, no lymph node metastasis is required.
|
After completion of induction treatment, up to 12 weeks
|
|
Partial Response Rate
大体时间:After completion of induction treatment, up to 12 weeks
|
The proportion of participants with non-muscle-invasive disease, including Ta, T1, or carcinoma in situ, confirmed by urine cytology or pathological biopsy, with no evidence of locally advanced or metastatic disease on imaging.
|
After completion of induction treatment, up to 12 weeks
|
|
Disease Progression Rate
大体时间:Up to 24 months after randomization
|
The proportion of participants with disease progression, defined as muscle-invasive bladder cancer confirmed by pathological biopsy, locally advanced disease, regional lymph node recurrence, distant metastasis, or bladder cancer-related death.
|
Up to 24 months after randomization
|
|
Overall Survival
大体时间:Up to 60 months after randomization
|
Overall survival is defined as the time from randomization to death from any cause.
|
Up to 60 months after randomization
|
|
Incidence and Severity of Adverse Events
大体时间:From the first dose through 30 days after the last dose, up to approximately 19 months
|
The incidence, severity, and relationship to study treatment of adverse events will be assessed according to the Common Terminology Criteria for Adverse Events.
|
From the first dose through 30 days after the last dose, up to approximately 19 months
|
|
Quality of Life Score
大体时间:Baseline to 24 months after randomization
|
Quality of life will be assessed using the EORTC QLQ-C30 questionnaire according to the study protocol.
|
Baseline to 24 months after randomization
|
|
Total Treatment Cost
大体时间:From randomization to the end of follow-up, up to 60 months
|
Total treatment cost will be calculated from randomization to the final follow-up according to the study protocol.
|
From randomization to the end of follow-up, up to 60 months
|
其他结果措施
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
2-Year Bladder-Intact Event-Free Survival Rate by Baseline HER2 IHC Category
大体时间:24 months after randomization
|
Pretreatment tumor HER2 expression will be assessed by immunohistochemistry and categorized as IHC 2+ or IHC 3+.
The percentage of participants meeting the 2-year bladder-intact event-free survival definition will be estimated separately for each HER2 IHC category.
Bladder-intact event-free survival is defined as being alive with an intact bladder and without muscle-invasive bladder cancer recurrence, regional lymph node recurrence, distant metastasis, radical cystectomy, or bladder cancer-related death.
The unit of measure is percentage of participants.
|
24 months after randomization
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (估计的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- TMU2H-RC48-TORI-MIBC-2026-035
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.